Last night, Bloomberg reported that Sanofi (SNY) had made a bid for Medivation (MDVN) but had been rebuffed, while noting that other companies–perhaps Gilead Sciences (GILD), Amgen (AMGN) or AstraZeneca (AZN)?–were also on the prowl. SunTrust Robinson Humphrey’s Peter Lawson explains why Medivation might be biotech’s most wanted:
Daniel Acker/Bloomberg News
Scarcity remains a key part of the story around Medivation. M&A is a common occurrence in biotech, over the past 3 years, 9 mid-cap peers have been acquired. While we believe Medivation could become the next big biotech on its own, our analysis would not be complete without laying out potential peer transactions to establish an M&A valuation. Our analysis suggests $62 ($51-71 range)…
Medivation is unique; a profitable mid-cap biotech: There are approximately nine profitable public U.S. biotech companies. Medivation is the only one that is a mid-cap (~$7bn), and a pure-play. In addition, Medivation has a cancer pipeline in two of the hottest areas of oncology immuno-oncology and genetically defined cancers (PARP inhibitor). We believe the stock should command a scarcity value.
Top 10 Blue Chip Stocks To Watch Right Now: Agenus Inc.(AGEN)
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. It offers Oncophage vaccine for the treatment of adjuvant renal cell carcinoma. The company?s products under development include Prophage series of cancer vaccines, which has been tested in Phase III clinical trials for the treatment of renal cell carcinoma (RCC) and metastatic melanoma, as well as has been tested in Phase I and Phase II clinical trials in various indications; and under Phase II clinical trials in glioma, a type of brain cancer, and adjuvant renal cell carcinoma. The Prophage series of cancer vaccines include R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its product candidate portfolio includes QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of non-small cell lung cancer, melanoma, malaria, and shingles, as well as in for the treatment of va rious infectious diseases and Alzheimer?s disease; and HerpV that completed Phase 1 clinical trial for the treatment of genital herpes. The company was formerly known as Antigenics Inc. and changed its name Agenus Inc. in January 2011 to reflect its existing product pipeline. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
- [By Lisa Levin]
Agenus (NASDAQ: AGEN) rose 22.99% to $3.37 after the company reported positive follow-on Phase 2 results for brain cancer vaccine.
Aeropostale (NYSE: ARO) shares jumped 18.23% to $10.18 after private equity firm Sycamore Partners bought a 7.96% stake in the company.
Top 10 Blue Chip Stocks To Watch Right Now: BlackRock, Inc.(BLK)
BlackRock, Inc. is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors. It also manages accounts for corporate, public, union and industry pension plans, insurance companies, third-party mutual funds, endowments, foundations, charities, corporations, official institutions, and banks. The firm also provides global risk management and advisory services. It manages separate client-focused equity, fixed income, and balanced portfolios. The firm also launches and manages open-end and closed-end mutual funds, offshore funds, ETFs, unit trusts, and alternative investment vehicles including hedge funds and structured funds. It invests in the public equity, fixed income, real estate, and alternative markets across the globe. The firm primarily invests in growth, value, and core stocks of small-cap, mid-cap, SMID-cap, large-cap and multi-cap companies. It employs a fundamental and quantitative analysis with a bottom-up stock picking approach to make its investments. The firm employs liquidity, asset allocation, balanced, real estate, and alternative strategies to make its investments. In real estate sector, the firm seeks to invest in Poland and Germany. BlackRock, Inc. was founded in 1988 and is based in New York City with additional offices in Boston, Massachusetts, London, United Kingdom, Brazil, Philadelphia, Pennsylvania, Plainsboro, New Jersey, and San Francisco, California.
- [By Tom Aspray, Senior Editor, MoneyShow.com]
Some of the emerging market ETFs are already up 7%, so far, this month, as it seems like others are drawing the same conclusions. Robert Kapito, co-founder of BackRock, Inc. (BLK), which has assets of $3.9 trillion, said that “The emerging markets are going to account for about 60 to 65% of the world’s growth over the next 20 years.”
Top Long Term Companies To Buy Right Now: Banner Corporation(BANR)
Banner Corporation operates as the bank holding company for Banner Bank and Islanders Bank, which provides commercial banking and financial products and services to individuals, businesses, and public sector entities primarily in the United States. It offers deposit products, including demand checking accounts, interest-bearing checking accounts, money market deposit accounts, regular savings accounts, certificates of deposit, cash management services, and retirement savings plans. The company also provides loan products, including commercial and multifamily real estate loans; residential mortgage loans; residential construction and land loans for professional home builders and developers; consumer loans, such as home equity lines of credit, automobile loans, boat and recreational vehicle loans, and loans secured by deposit accounts; commercial business loans; and agricultural loans. In addition, it engages in mortgage banking operations through the origination and sale of one- to four-family and multi-family residential loans. As of December 31, 2015, Banner Bank operated 199 branch offices and 9 loan production offices in Washington, Oregon, and Idaho; and Islanders Bank conducted business from 3 locations in San Juan County, Washington. Banner Corporation was founded in 1890 and is based in Walla Walla, Washington.
- [By Ben Levisohn]
The twenty stocks in Worth’s basket are: Ameriprise Financial (AMP) Bank of America, Banner (BANR), Citigroup, Citizens Financial Group (CFG), East West Bancorp (EWBC), First NBC Bank Holding (FNBC), HFF (HF), KeyCorp(KEY), Legacy Texas Financial Group (LTXB), Lincoln National (LNC), Morgan Stanley, Old National Bancorp (ONB), PacWest Bancorp (PACW), PNC Financial Services Group (PNC), Principal Financial Group (PFG), Stifel Financial (SF), SVB Financial Group (SIVB), TCF Financial (TCB), and Wells Fargo.
Top 10 Blue Chip Stocks To Watch Right Now: Banco Santander, S.A.(SAN)
Banco Santander, S.A., together with its subsidiaries, provides various retail and commercial banking products and services for individual and corporate clients. The company offers demand and time deposits, and current accounts; mortgages and auto finance, personal loans, and loans to buy durable goods; and debit and credit cards. It also provides cash management, trade finance, financing and custody, and bond and securitization origination services; originates and distributes corporate loans and structured financings; and offers corporate finance services for mergers and acquisitions, equities markets, and investment solutions through derivatives, as well as asset and capital structuring. In addition, the company is involved in the corporate banking, treasury, and investment banking activities; sale and distribution of fixed income and equity derivatives, interest rates, and inflation; trading and hedging of exchange rates an d short-term money markets for wholesale and retail customers; and brokerage of equities, and derivatives for investment and hedging solutions. Further, it offers asset management, private banking, and payment capture and processing services, as well as mobile and online banking services. It operates through 13,030 branches worldwide. The company was formerly known as Banco Santander Central Hispano S.A. and changed its name to Banco Santander, S.A. in June 2007. Banco Santander, S.A. was founded in 1857 and is headquartered in Madrid, Spain.
- [By Alanna Petroff]
The police linked the theft at Barclays (BCS) to another attempt to steal money from a Santander (SAN) branch in London, which led to the arrest of 12 men last week.
Top 10 Blue Chip Stocks To Watch Right Now: BioMarin Pharmaceutical Inc.(BMRN)
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. The company?s commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis (MPS) VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It develops GALNS, an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-673, a Phase I/II clinical trial product for the treatment of cancer; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of Kuvan and other products containing 6R-BH4 and PEG-PAL for PKU. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in Novato, California.
- [By Ben Levisohn]
SRPT’s dystrophin argument strongly challenged and largely invalidated by the FDA. Recall, the panelists were very critical of dystrophin data for BioMarin Pharmaceutical (BMRN), and we expect a similar level of scrutiny. The FDA points out two major concerns with Sareptas method of quantifying dystrophin expression: 1) reconciling the low correlation between Western blot vs. immunofluroesscence, and 2) overexaggeration of the data. To the first point, not only was the correlation between the two methods not strong, when considering Western blot as a more relevant and reliable quantitative measurement for dystrophin expression, FDA sees the resulting 0.9% (of normal) after 3.5 years as disappointing. To the latter point, the applicants suggestion of an 11.6-fold increase in de novo dystrophin production assumes a baseline of 0.08% dystrophin level, which is below the instruments detection level of 0.25%.
- [By Ben Levisohn]
Importantly – it reinforces our view that large cap biotech may have gotten too cheap and big pharma companies are ready and poised to do more deals as they are flush with cash, in a low interest rate environment, and need pipeline…This is positive for other large caps as well including Celgene (CELG), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX), etc.
Top 10 Blue Chip Stocks To Watch Right Now: Teva Pharmaceutical Industries Limited(TEVA)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic medicines, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the womens health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinsons disease; Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders; Fentora庐/Effentora for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer; and Zecuity, a prescription transdermal system for the acute treatment of migraine with or without aura in adults. This segments products in the respiratory market include ProAir, ProAir Respiclick, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Granix, Trisenox, Synribo, Lonquex, Myocet, Eporatio, Tevagrastim/Ratiograstim, and Trisenox products in the oncology market. This segment also offers a portfolio of products in the womens health category, which includes ParaGard, Plan B One-Step, OTC/Rx, Zoely, Seasonique, and Ovaleap, as well as other products. Teva Pharmaceutical Industries Limited has alliances and other arrangements with Takeda Pharmaceutical Company Limited and Procter & Gamble Company. The company was founded in 1901 and is headquartered in Petach ! Tikva, Israel.
- [By Johanna Bennett]
UBSs Marc Goodman weighed in today on Teva Pharmaceuticals (TEVA) following yesterdays run by the stocks on the heels of the better-than-expected 1Q financial results by the drug maker.
Offered up these highlight from the conference call with management, proclaiming that there are four things we believe investors need to hear.
[Management sounds] confident in the AGN deal going through and has identified buyers for the majority of products to be divested. While divestitures are higher than expected, management will cut more costs to maintain the previously expected bottom line accretion. The U.S. generic drug pricing environment has not changed, and management still sees about 4% impact in 2016, which is similar to levels last year. The underlying base business for Teva is performing as expected, and it still expects sustainable growth in the global generics business of more than 5%. That includes a 10% gain from new products offset by a 5% hit from price/volume.
Still, Goodman encourages investors to wait and see before buying the stock.
Mgt sounded confident that the AGN generics deal should move forward, and Teva needs the cost synergies to help offset the potential Copaxone generic impact. But also Teva is significantly increasing its exposure to generics, as investors are incrementally more skeptical of the sector, so we would expect investors to take a wait and see attitude on numbers. In addition to the deal, the focus is on the generic challenges to Copaxone (IPR process/Sept trial), which we think will remain an overhang on the stock.
Teva climbed more than 5% Monday and inched a bit higher today to trade at $52.85 in recent marker action. The shares have fallen 19.5% since the start of the year.
- [By Kanak Kanti, De]
Last week, Israel-based Teva Pharmaceuticals’ (NYSE: TEVA ) generic product portfolio received a major boost after the Food and Drug Administration approved the company’s generic version of Xeloda, a cancer drug. Roche’s (NASDAQOTH: RHHBY ) Xeloda is an orally administered chemotherapy treatment for colorectal and breast cancers that have metastasized. Given the fact that Xeloda generated $1.6 billion in sales for Roche in 2012, Teva’s generic version has significant potential
- [By Ben Levisohn]
Allerganmgmt is considering a range of capital deployment alternatives. The focus on the conference call was around future capital deployment. Mgmt remains highly optimistic the Teva Pharmaceutical Industries (TEVA) deal will close by late 1H16, noting both mgmt teams are absolutely aligned on getting the deal done and the deal proceeds will be after-tax net cash/equity of ~$36B. Mgmts is currently looking at a broad range of capital deployment options including debt pay down, share buyback and M&A. In our view,Allergan will likely put the TEVA proceeds to work through a mix of these options. The company has ~$6B of debt maturing in the next 2-years which it could look to repay and there are a few small to mid-size M&A targets thatAllergan could look to acquire. In terms of timing, mgmt commented that it would not hesitate for the right opportunity which suggests to us smaller bolt-on transactions arent gated by the completion of TEVA dea l.
Top 10 Blue Chip Stocks To Watch Right Now: Urban Outfitters Inc.(URBN)
Urban Outfitters Inc. operates lifestyle specialty retail stores under the Urban Outfitters, Anthropologie, Free People, Terrain, and BHLDN brand names in the United States, Canada, and Europe. Its Urban Outfitters stores sell women?s and men?s fashion apparel, footwear, accessories, and gifts, as well as apartment wares, such as rugs, pillows, shower curtains, books, candles, and novelties to young adults aged 18 to 28; and Anthropologie stores provide women?s casual apparel and accessories, shoes, gifts, and decorative items, as well as home furnishings, including furniture, rugs, lighting, antiques, table top items, and bedding to women aged 28 to 45. The company?s Free People stores primarily offer Free People branded merchandise mix of casual women?s apparel, intimates, shoes, accessories, and gifts to young contemporary women aged 25 to 30; Terrain store provides lifestyle home and garden products, antiques, live plants, flowers, wellness products, and accessori es, as well as landscape and design service solutions; and BHLDN store offers a range of weeding collections consisting of wedding gowns, bridesmaid frocks, party dresses, assorted jewelry, headpieces, footwear, lingerie, and decorations. As of January 31, 2012, it operated 197 Urban Outfitters stores, 168 Anthropologie stores, 62 Free People stores, 1 Terrain garden center, and 1 BHLDN store. The company also operates a wholesale business under the Free People brand name that distributes apparel to other retailers and department stores in the United States. In addition, it markets its brands directly to consumers through its e-commerce Websites, including urbanoutfitters.com, anthropologie.com, freepeople.com, urbanoutfitters.co.uk, urbanoutfitters.de, urbanoutfitters.fr, anthropologie.eu, shopterrain.com, and bhldn.com, as well as through its Urban Outfitters, Anthropologie, and Free People catalogs. The company was founded in 1970 and is based in Philadelphia, Pennsylvani a.< /p> Advisors’ Opinion:
- [By Ben Levisohn]
Shares of Urban Outfitters (URBN) are soaring today following its earnings release last night–and big part of the reason is its success with millennials. UBS analystMichael Binetti and team explain:
Urban Outfitters reported 2Q EPS of $0.66, well ahead of our $0.52 and Street $0.55. Same-store sales increased +1% (vs UBSe -3.9%; Street -1.1%) with Urban Outfitters+5% (UBSe -1%),Anthropologie -3% (UBSe -6%), and Free People flat (UBSe -7%)…
We’re increasing our target P/E to 16x (in line with Urban Outfitters’ 3-yr avg P/E) from 14x previously) due to inflecting sales at the core Urban chain (40% of sales). We’re raising our FY18E EPS to $2.26 from $2.13. The key debate for URBN’s stock from here is whether it deserves a premium to its 3-yr avg P/E (w/the stock likely to open higher to reflect Street numbers likely being revised higher in the near term). While we’re impressed with Urban Outfitters, we think a P/E premium is easier to justify if Urban Outfitters can show more progress at Anthropologie (42% of sales) and Free People (8% of sales). That said, US department stores’ lack of traction with millennials is making Urban Outfitters a more important destination for strong apparel/footwear brands (adidas, Vans, CK)which could result in a more extended sales recovery at the Urban Outfitters chain than our model currently assumes, and which could warrant a higher P/E.< /p>
Binetti raised his price target on Urban Outfitters to $36 from $30 while leaving his rating at Neutral.
Shares of Urban Outfitters have soared 16% to $36.14 at 3:04 p.m. today.
Top 10 Blue Chip Stocks To Watch Right Now: FEI Company(FEIC)
FEI Company supplies scientific instruments for nanoscale imaging, analysis, and prototyping that enable research, development, and manufacturing in industrial, academic, and research institutional applications. Its products include transmission electron microscopes and scanning electron microscopes (SEMs); DualBeam systems, which include a SEM and focused ion beam system (FIB) on a single platform; and stand-alone FIBs. The company?s Electronics segment offers products used in laboratories to enhance new product development and increase yields by enabling 3D wafer metrology, defect analysis, root cause failure analysis, and circuit edit for modifying device structures in the semiconductor equipment and related industries, such as manufacturers of data storage equipment, solar panels, and light-emitting diodes. FEI Company?s Materials Science segment provides atomic-level resolution images and permit development, analysis, and production of products that are used in mini n g for automated mineralogy, and oil and gas exploration to universities, and public and private research laboratories, as well as natural resources, petrochemicals, metals, automobiles, aerospace, and forensics industries. The company?s Life Sciences segment offers ultra-high resolution imaging products that allow structural and cellular biologists and drug researchers to create 3D reconstructions of biological structures, as well as used in particle analysis, and a range of pathology and quality control applications. FEI Company?s Service and Components segment provides technical support products and customers. The company sells its products through independent agents, distributors, and representatives in the United States, Canada, Europe, the Asia-Pacific region, and internationally. FEI Company was founded in 1971 and is headquartered in Hillsboro, Oregon.
- [By Lisa Levin]
FEI Company (NASDAQ: FEIC) shares were also up, gaining 14 percent to $108.00 as the company agreed to be acquired by Thermo Fisher Scientific Inc. (NYSE: TMO) for $4.2 billion.
Top 10 Blue Chip Stocks To Watch Right Now: DIRECTV(DTV)
DIRECTV provides digital television entertainment in the United States and Latin America. The company provides direct-to-home (DTH) digital television services, as well as multi-channel video programming distribution services in the United States. It offers various channels of digital-quality video entertainment and CD-quality audio programming directly to subscribers’ homes or businesses, as well as video-on-demand services; and approximately 160 national high-definition television channels and 4 3D channels. The company also provides premium professional and collegiate sports programming, such as the NFL SUNDAY TICKET package, which allows subscribers to view the NFL games. In addition, it offers DTH digital television services in Latin America and the Caribbean, including Puerto Rico. The company provides its local and international programming under the DIRECTV and SKY brand names. As of December 31, 2010, it served approximately 19.2 million subscribers in the United States; and 8.9 million subscribers in Latin America. The company was founded in 1990 and is based in El Segundo, California.
- [By Christopher Freeburn]
Service disruptions on DirecTV’s (DTV) website temporarily interfered with subscribers’ ability to stream National Football League (NFL) games online for the last two Sundays.
Top 10 Blue Chip Stocks To Watch Right Now: Peak Resorts, Inc.(SKIS)
Peak Resorts, Inc., incorporated on September 24, 1997, is a holding company. The Company, through its subsidiaries, owns or leases, and operates day ski and overnight drive ski resorts in the United States. As of April 30, 2015, the Company operated 13 ski resorts, including five overnight drive ski resorts and eight day ski resorts located across six states, including Wildwood and Weston, Missouri; Bellefontaine and Cleveland, Ohio; Paoli, Indiana; Blakeslee and Lake Harmony, Pennsylvania; Bartlett, Bennington and Pinkham Notch, New Hampshire, and West Dover, Vermont. The Company also has an 18 hole golf course in West Dover, Vermont. In addition, it manages hotels in Bartlett, New Hampshire and West Dover, Vermont, and operates a restaurant in Lake Harmony, Pennsylvania.
As of April 30, 2015, its resorts covered an area of 1,650 acres. Its activities, services and amenities include skiing, snowboarding, terrain parks, food and beverage, tubing, dining, lodg ing, equipment rentals and sales, ski and snowboard instruction, mountain biking and other summer activities. The Company also offers non-ski activities, such as golf, roller coasters, swimming and zip rides. Its ski resorts include Hidden Valley, Snow Creek, Paoli Peaks, Mad River, Boston Mills, Brandywine, Crotched Mountain, Jack Frost, Big Boulder, Attitash, Mount Snow, Wildcat Mountain and Alpine Valley. Events hosted by the Company include Dew Tour, X-Games, Tough Mudder, SAM Cutters Camp, Transworld Trans-am Snowboard Event, Mountain Dew Vertical Challenge, Special Olympics Games, Military Salutes, and the United States National Mountain Biking Championships.
- [By Monica Gerson]
Peak Resorts Inc (NASDAQ: SKIS) is projected to report its quarterly earnings at $0.40 per share on revenue of $42.59 million.
BMC Stock Holdings Inc (NASDAQ: STCK) is expected to post its quarterly earnings at $0.17 per share on revenue of $449.59 million.